30 closest matches · ranked by relevance
Chronic Hepatitis B
Primary: Mean Change in Quantitative Hepatitis B Surface Antigen (qHBsAg) — 0.0; 0.0; 0.0; 0.0 log10 IU/mL — p=1.000
Gastroenteritis Norovirus
Primary: Time to Initial Clinical Resolution of Norovirus Symptoms — 19; 11 days — p=0.459
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroclearance at Week 72 Without Restarting NA Treatment — 0.0; 0.0 Percentage of participants
NASH - Nonalcoholic Steatohepatitis · Cirrhosis · Portal Hypertension
Primary: Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT) — 190…
Hepatitis B, Chronic
Primary: Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144 — 77.0 Percentage of…
Hyperammonemia
Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 6; 6; 7; 8 participants
NASH - Nonalcoholic Steatohepatitis
Primary: Patient Incidence of Adverse Events for TERN-201 Versus Placebo — 9; 11; 8 Participants
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.5; 100 percentage of participants
Pitt Hopkins Syndrome
Primary: Safety and Tolerability — 15; 0; 4; 12 Participants
Hepatitis B · Liver Transplantation
Primary: HBV Recurrence — 0; 0 participants
Chronic Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) — 100 percentage of participants
Hepatitis B
Primary: Change of the Rates of Participants Who Adherent to Recommended Clinical Care for the Monitoring of Chronic HBV Infection — 200; 113; 225; 140 Participants
Liver Transplant · Hepatitis C
Primary: Adverse Events Due to Sofosbuvir/Velpatasvir (Epclusa) — 0; 0 Participants
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) — 25; 18 participants — p=0.34
Lymphoma, Non-Hodgkin's
Primary: Overall Response Rate — 53.8 percentage of participants
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
HIV/AIDS · Aging · Mild Cognitive Impairment
Primary: Feasibility - Session Attendance — 5; 5 Participants
Prostate Cancer
Primary: Safety Assessed by Development of Adverse Events and Dose-limiting Toxicity to Determine Maximum Tolerated Dose — 3; 3; 6; 0 Participants
Hepatitis B
Primary: HBsAG Prevalence — 22 Participants
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Primary: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis…
Niemann-Pick Disease, Type C
Primary: Efficacy of Adrabetadex (VTS-270) to Reduce Plasma Levels of a Conjugated Bile Acid, Known as 5α-cholanic Acid-3β, 5α, 6β-triol N-(Carboxymethyl)-Amide — 32.6; 87.9 ng/ml
Hepatitis B Chronic Infection · Pregnancy
Primary: Percentage of Infants With Hepatitis B Infection at 6 Months of Age — 0; 3 Participants
Hepatitis B, Chronic
Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping All Study Interventions at the End of…
Thrombotic Microangiopathies · Hematologic Diseases
Primary: The Incidence of TA-TMA. — 5; 15 Participants
Nonalcoholic Steatohepatitis
Primary: Histological Improvement of at Least 2 Points in NAFLD Activity Score (NAS) on Liver Biopsy After One Year. — -1.6; -0.1 NAS score units
Jaundice, Neonatal
Primary: Efficacy of Phototherapy — 116; 135 treatment days
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
Tuberculosis · HIV Infections
Primary: Number of Participants With Incident Tuberculosis — 20; 34 Participants
Congenital Bleeding Disorder · Haemophilia B
Primary: Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU) — 0; 0 Participants
Hepatitis D, Chronic
Primary: Double-blind: Part 1: Percentage of Participants With HDV Ribonucleic Acid (RNA) >=2 log10 IU/mL Decline From Baseline or HDV RNA Target Not Detected (TND) in…